DISCOVERING NEW POSSIBILITIES—RESEARCH & DEVELOPMENT
The combined efforts of many skilled people and a strong relationship with the global Key Opinion Leader (KOL) community work together to continually increase the quality and urgency of Taiho Oncology’s research.
DISCOVERY AND PRECLINICAL RESEARCH DIVISION: TSUKUBA AREA
As a specialty pharma in the field of oncology, Taiho Pharmaceutical is committed to creating anti-cancer drugs with diverse mechanisms of action. In the field of cancer metabolism, the company harnesses the abundant experience and expertise it accumulated in the development of UFT and TS-1, to discover highly potent anti-cancer agents with novel mechanisms of action.
In the area of molecular targeted drugs, the company explores cancer biology at the molecular level and integrates knowledge of chemistry, biology and biomarker research with the goal of discovering novel molecular targeted drugs with a good safety profile that are highly beneficial and specific against particular cancers. At the same time, the company works to establish state-of-the-art drug discovery platforms.
The Tsukuba Area also focuses on research to discover drugs that can be fundamental therapeutic agents, by clarifying disease mechanisms in a new way in the areas of allergy/immunology and urology.
DISCOVERY AND PRECLINICAL RESEARCH DIVISION: TOKUSHIMA AREA
The Discovery and Preclinical Research Division: Tokushima Area pursues efficacy, safety, and quality in order to advance drug candidates from the lab, through the clinic, to the marketplace for contribution to patient care.
CLINICAL DEVELOPMENT DIVISION
The Clinical Development Division is responsible for planning and conducting clinical trials to develop novel drugs, and obtaining regulatory approval. Drug candidates are evaluated clinically through all phases of development processes, with the utmost attention paid to the safety and ethical treatment of patients who cooperate in trials.
KITAJIMA MANUFACTURING FACILITY
The new Kitajima Manufacturing Facility will serve as a production centre for anti-cancer drugs. This 29,000-square- foot production centre is furnished with state-of-the-art equipment for the production of solid preparations, and houses offices and a quality control centre.
The Facility is surrounded by a park and a tree-lined promenade that can be enjoyed by local residents, or used as a public evacuation site in the event of an emergency.
The Kitajima Facility strikes a deliberate balance between world-class technology, environmental awareness, and community involvement.